Video

AHA/ACC prevention guidelines: Clinician perspective


 

Soon after the AHA/ACC cardiovascular prevention guidelines were released, they were engulfed in criticism and controversy, especially for the new risk calculator. Meanwhile, physicians have to decide how to incorporate the updated guidelines into their practice.

In this interview, Dr. Eugenia Gianos, director of Preventive Cardiology Consult Service at NYU Langone Medical Center, New York, shares her thoughts on the risk calculator, the guidelines, and their impact on practice.

Recommended Reading

Hidradenitis suppurativa linked to metabolic syndrome
MDedge Endocrinology
Obesity paradox may exist in hypertensive patients with diabetes
MDedge Endocrinology
Large U.K. database shows sulfonylurea mortality link
MDedge Endocrinology
ACCORD: Younger, not older, age linked to higher cardiovascular death rates
MDedge Endocrinology
FDA moves to reduce or remove unhealthy trans fats from foods
MDedge Endocrinology
CV events scuttle bardoxolone for diabetic kidney disease
MDedge Endocrinology
Combined angiotensin inhibition raises hyperkalemia, acute kidney injury risks
MDedge Endocrinology
ACC-AHA cardiovascular prevention guidelines drop cholesterol treatment goals
MDedge Endocrinology
Abandon LDL targets? Not yet
MDedge Endocrinology
Guideline authors, AHA-ACC leaders confident in risk calculator
MDedge Endocrinology